Is Avalo Therapeutics, Inc. (AVTX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.2% / 30% | 42.0% / 30% | 0.2% / 30% | 6843.54% / 5% | ✗ NOT HALAL |
| DJIM | 0.2% / 33% | 42.0% / 33% | 0.2% / 33% | 6843.54% / 5% | ✗ NOT HALAL |
| MSCI | 0.4% / 33% | 89.3% / 33% | 0.4% / 33% | 6843.54% / 5% | ✗ NOT HALAL |
| S&P | 0.2% / 33% | 42.0% / 33% | 0.2% / 33% | 6843.54% / 5% | ✗ NOT HALAL |
| FTSE | 0.4% / 33% | 89.3% / 33% | 0.4% / 50% | 6843.54% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -33461.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -72.4% | |
| Return on Assets (ROA) | -34.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$49M |
| Free Cash Flow | -$49M |
| Total Debt | $568,000 |
| Debt-to-Equity | 0.5 |
| Current Ratio | 8.1 |
| Total Assets | $151M |
Price & Trading
| Last Close | $13.95 |
| 50-Day MA | $15.50 |
| 200-Day MA | $13.09 |
| Avg Volume | 449K |
| Beta | 0.9 |
|
52-Week Range
$3.39
| |
About Avalo Therapeutics, Inc. (AVTX)
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Avalo Therapeutics, Inc. (AVTX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Avalo Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Avalo Therapeutics, Inc.'s debt ratio?
Avalo Therapeutics, Inc.'s debt ratio is 0.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.4%.
What are Avalo Therapeutics, Inc.'s key financial metrics?
Avalo Therapeutics, Inc. has a market capitalization of $317M, and revenue of $441,000. Return on equity stands at -72.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.